Treating weight loss in extensive-stage small cell lung cancer
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests whether adding a drug called nanocrystalline megestrol to standard chemotherapy and immunotherapy can help patients with extensive-stage small cell lung cancer who are losing weight or have poor appetite. It aims to improve nutrition and overall well-being during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have been diagnosed with extensive-stage small cell lung cancer.
- You have not had chemotherapy for metastatic disease before, but you may have had it in the past if it was for early-stage cancer and it's been more than 6 months since treatment ended.
- You are losing weight or have a poor appetite, or have signs of inflammation in your body.
- Your overall health is reasonably good, with adequate organ function (kidneys, liver, heart, lungs, and blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of benmelstobart (an immunotherapy drug), anlotinib (a targeted therapy that blocks blood vessel growth), chemotherapy, and chest radiation for people with extensive-stage small cell lung cancer (cancer that has spread beyond one lung). The goal is to see if this combination helps shrink tumors and control the disease better than standard care.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and chest radiation for people with extensive-stage small cell lung cancer (SCLC) that has spread. The goal is to see if this combination helps shrink or control the cancer longer.
This trial tests a drug called megestrol acetate, which is a type of progesterone that can help increase appetite and reduce weight loss. It is for people with a certain type of lung cancer (small cell lung cancer) that has spread, especially if they are experiencing early signs of weight loss or frailty.
This study tests whether adding a drug that boosts appetite and weight to standard lung cancer treatment helps people with advanced small cell lung cancer who are experiencing weight loss and poor appetite. It aims to improve quality of life and treatment outcomes.
This study is testing whether a medication called megestrol acetate (a type of hormone that can boost appetite and help with weight gain) can improve outcomes for people with advanced non-small cell lung cancer who are malnourished. It is used as part of first-line treatment, meaning before any chemotherapy for the advanced cancer.
This study tests a medicine called nanocrystalline megestrol acetate to see if it can help improve appetite and promote weight gain in people with advanced non-small cell lung cancer who are losing weight. If you qualify, you would receive this treatment alongside your regular care to help you feel better and maintain your strength.
Hear when a new SCLC, Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.